Case report: ex vivo tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinoma
Frontiers in Oncology · 04.01.2024 · 13
DOI: 10.3389/fonc.2023.1267650 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 04.01.2024. Verfasst von Marwah Al-Aloosi und 12 weiteren Autor:innen. Beteiligte Einrichtung: SEngine Precision Medicine, Seattle, WA, United States. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Patients presenting with stage 4 ovarian carcinoma, including low-grade serous disease, have a poor prognosis. Although platinum-based therapies can offer some response, these therapies are associated with many side effects, and treatment resistance often develops. Toxic side effects along with disease progression render patients unable to receive additional lines of treatment and limit their options to hospice or palliative care. In this case report, we describe a patient with an unusual case of metastatic low-grade serous ovarian cancer with some features of high-grade disease who had received four previous lines of treatment and was suffering from atelectasis, pulmonary embolism, and hydronephrosis. A CLIA-certified drug sensitivity assay of an organoid culture derived from the patient’s tumor (PARIS ® test) identified several therapeutic options, including the combination of fulvestrant with everolimus. On this treatment regimen, the patient experienced 7 months of stable disease and survived nearly 11 months before succumbing to her disease. This case emphasizes the clinical utility of ex vivo drug testing as a new functional precision medicine approach to identify, in real-time, personalized treatment options for patients, especially those who are not benefiting from standard of care treatments.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- SEngine Precision Medicine, Seattle, WA, United States.
- Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, United States.
- Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, United States.
- Private Health Management, Los Angeles, CA, United States.
Förderung
- NCI NIH HHS
Zitieren
APA
Al-Aloosi, M., Prechtl, A. M., Chatterjee, P., Bernard, B., Kemp, C. J., Rosati, R., Diaz, R. L., Appleyard, L. R., Pereira, S., Rajewski, A., McDonald, A., Gordon, E. J., & Grandori, C. (2024). Case report: ex vivo tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinoma. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1267650
Vancouver
Al-Aloosi M, Prechtl AM, Chatterjee P, Bernard B, Kemp CJ, Rosati R, et al. Case report: ex vivo tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinoma. Frontiers in Oncology. 2024;13. doi:10.3389/fonc.2023.1267650
BibTeX
@article{AlAloosi2024,
author = {Al-Aloosi, Marwah and Prechtl, Amanda M and Chatterjee, Payel and Bernard, Brady and Kemp, Christopher J and Rosati, Rachele and Diaz, Robert L and Appleyard, Lauren R and Pereira, Shalini and Rajewski, Alex and McDonald, Amber and Gordon, Eva J and Grandori, Carla},
title = {Case report: ex vivo tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinoma},
journal = {Frontiers in Oncology},
year = {2024},
volume = {13},
doi = {10.3389/fonc.2023.1267650}
}
EUVIMED